scholarly journals PD34-07 ENZALUTAMIDE IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PATIENTS WHO RECEIVED PRIOR ANTIANDROGEN THERAPY: POST HOC ANALYSIS OF ARCHES

2021 ◽  
Vol 206 (Supplement 3) ◽  
Author(s):  
Neal D. Shore ◽  
Taro Iguchi ◽  
Arnauld Villers ◽  
Antonio Alcaraz ◽  
Francisco Gomez-Veiga ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Post Hoc Analysis ◽  
Hormone Sensitive ◽  
Post Hoc ◽  
Antiandrogen Therapy

scholarly journals Post-hoc analysis of changes in renal function of prostate cancer patients: Focus on androgen deprivation therapy

2020 ◽  
Author(s):  
Yoshiyuki Miyazawa ◽  
Yoshitaka Sekine ◽  
Seiji Arai ◽  
Daisuke Oka ◽  
Hiroshi Nakayama ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Renal Function ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Estimated Glomerular Filtration Rate ◽  
Androgen Deprivation ◽  
University Hospital ◽  
Post Hoc Analysis ◽  
Significant Difference ◽  
Post Hoc

Abstract Background To investigate the association between androgen deprivation therapy (ADT) and changes in the estimated glomerular filtration rate (eGFR) in male Japanese prostate cancer patients, based on post-hoc analysis of data from a previous prospective study.Methods From among 103 prostate cancer patients in whom renal function changes were tracked over 5 years, 88 were divided into a group who completed ADT within 3 years (short ADT group; n = 47) and a group who continued with ADT for more than 5 years (continuous ADT group; n = 41). We compared the groups in terms of the eGFR, calculated based on age and serum creatinine (mg/dL), before ADT initiation and every other year over the next 5 years. This study was approved by the Ethics Committee for Clinical Studies of Gunma University Hospital (Approval No: 8 − 5).Results The eGFR decreased by 4.91 and 2.89 ml/min in the short and continuous ATD groups, respectively, over the 5-year period following ADT initiation. The respective decreases in the eGFR were 0.98 and 0.58 ml/min/year. No significant difference in the eGFR was observed between the two groups at any measurement point.Conclusions ADT patients showed a decrease in the eGFR of 0.58–0.98 ml/min/y over a 5-year period, which is about twice as high as that of normal Japanese males. No significant difference in the eGFR by ADT duration was observed.

The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 5071-5071
Author(s):  
Andrew J. Armstrong ◽  
Taro Iguchi ◽  
Arun Azad ◽  
Arnauld Villers ◽  
Boris Alekseev ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Disease Spread ◽  
Post Hoc Analysis ◽  
Secondary Endpoints ◽  
Hormone Sensitive ◽  
Baseline Characteristics ◽  
Post Hoc ◽  
Docetaxel Chemotherapy ◽  
Clinical Trial Information

5071 Background: In ARCHES (NCT02677896), ENZA + ADT reduced the risk of radiographic progression and improved secondary clinical outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) with variable patterns of disease spread over placebo (PBO) + ADT. This post hoc analysis aimed to evaluate the efficacy of ENZA + ADT in patients with bone oligometastatic mHSPC compared to polymetastatic mHSPC in ARCHES. Methods: Patients with mHSPC (n = 1150) were randomized 1:1 to ENZA (160 mg/day) + ADT or PBO + ADT, stratified by disease volume and prior docetaxel chemotherapy. This post hoc analysis included patients with bone metastases only, categorized as oligometastatic (1–≤5 metastases) or as polymetastatic (≥6 metastases) based on central review at screening. Efficacy outcomes were compared across treatment arms. Results: Of the ARCHES population with bone metastases (n = 512), the largest subgroup included patients with ≤5 metastases (ENZA + ADT, n = 160; PBO + ADT, n = 136). Baseline characteristics were generally comparable between treatment arms and across subgroups. When compared to PBO + ADT, ENZA + ADT improved rPFS and secondary endpoints in patients with ≤5 metastases (Table). Similar results were observed across other oligometastatic subgroups (1–≤4) as well as in polymetastatic disease (≥6). The safety profile of ENZA + ADT versus PBO + ADT was similar across subgroups and consistent with previous findings. Conclusions: This post hoc analysis demonstrates that ENZA + ADT provides clinical benefit across bone oligometastatic as well as polymetastatic mHSPC, supporting the utility of ENZA irrespective of metastatic burden in the ARCHES study. Clinical trial information: NCT02677896. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document